Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
This invention relates to methods and compositions for the prevention and treatment of Type 2 diabetes and cardiovascular disease with diabetic or pre-diabetic conditions or symptoms associated therewith using both a PPAR gamma agonist and a PPAR alpha agonist or a compound which activates both PPAR gamma and PPAR alpha . A preferred PPAR gamma agonist is a thiazolidinedione compound, including BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and congeners, analogs, derivatives and pharmaceutically acceptable salts thereof. A preferred PPAR alpha agonist is a fibrate compound including gemifbrozil, fenfibrate, bezofibrate, clofibrate, ciprofibrate, and analogs, derivatives and pharmaceutically acceptable salts thereof
21812265
Applicant(s): Ligand Pharm Inc [Us]
Alternative title(s) : (de) Vorbeugung oder behandlung von typ 2 diabetes oder kardiovaskulärer erkrankung mit ppar modulatoren (fr) Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
Patent number | Country code | Kind code | Date issued |
EP0930882 | EP | A2 | 1999-07-28 |
WO9805331 | WO | A3 | 1998-05-07 |
AU4050797 | AU | A | 1998-02-25 |
WO9805331 | WO | A2 | 1998-02-12 |